Response to Guo et al, “Response to Huang et al’s ‘Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the Chinese Rheumatism Data Center (CRDC)’”
Response to Guo et al, “Response to Huang et al’s ‘Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the Chinese Rheumatism Data Center (CRDC)’”. // Journal of the American Academy of Dermatology. – URL: https://www.sciencedirect.com/science/article/pii/S0190962226030185?dgcid=rss_sd_all
Response to Guo et al, “Response to Huang et al’s ‘Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the Chinese Rheumatism Data Center (CRDC)’”. Journal of the American Academy of Dermatology. https://www.sciencedirect.com/science/article/pii/S0190962226030185?dgcid=rss_sd_all
“Response to Guo et al, “Response to Huang et al’s ‘Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the Chinese Rheumatism Data Center (CRDC)’”.” Journal of the American Academy of Dermatology.
@article{article89968,
title = {Response to Guo et al, “Response to Huang et al’s ‘Real-world efficacy and safety of tofacitinib on the progression of skin sclerosis in patients with systemic sclerosis: An analysis of national multicenter data from the Chinese Rheumatism Data Center (CRDC)’”},
journal = {Journal of the American Academy of Dermatology},
url = {https://www.sciencedirect.com/science/article/pii/S0190962226030185?dgcid=rss_sd_all}
}